You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Personalizing Cancer Care in Nonmetastatic Castration-Resistant Prostate Cancer

  • Authors: Alicia K. Morgans, MD, MPH; Steven P. Ludlow, PharmD, BCOP, BCPS; Frank dela Rama, RN, MSN, CNS, AGN-BC, AOCNS
  • CME / ABIM MOC / CE Released: 1/25/2022
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 1/25/2023
Start Activity


Target Audience and Goal Statement

This activity is intended for oncologists, urologists, nurses, and nurse practitioners.

The goal of this activity is to improve the knowledge and confidence of oncologists, urologists, and other members of the healthcare team in creating more patient-centered treatment plans for nonmetastatic castration-resistant prostate cancer (nmCRPC) and actively engaging patients and caregivers in care-planning discussions to balance clinical outcomes with maintenance of quality of life.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Benefit of shared decision-making (SDM) in optimizing outcomes for patients with nmCRPC
    • Potential adverse effects of oral anti-androgen agents used in the management of nmCRPC
  • Have greater competence related to
    • Improving adherence to life-prolonging oral anti-androgen therapies
  • Demonstrate greater confidence related to
    • Interprofessional team collaboration when using SDM to empower patients with nmCRPC and their caregivers to be engaged in care decisions


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Alicia K. Morgans, MD, MPH

    Medical Oncologist
    Medical Director, Survivorship Program
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Disclosures

    Disclosure: Alicia K. Morgans, MD, MPH, has the following relevant financial relationships: 
    Advisor or consultant for: AAA; Astellas; AstraZeneca; Bayer; Blue Earth; Clovis; Dendreon; Janssen; Lantheus; Merck; Myovant; Myriad; Novartis; Pfizer; Sanofi; Seagen Inc., formerly Seattle Genetics, Inc.
    Grants for clinical research from: Astellas; Bayer; Dendreon; Sanofi; Seagen Inc., formerly Seattle Genetics, Inc.

Faculty

  • Steven P. Ludlow, PharmD, BCOP, BCPS

    Medical Oncology Clinical Pharmacy Specialist
    H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida

    Disclosures

    Disclosure: Steven P. Ludlow, PharmD, BCOP, BCPS, has no relevant financial relationships.

  • Frank dela Rama, RN, MSN, CNS, AGN-BC, AOCNS

    Clinical Nurse Specialist
    Palo Alto Medical Foundation
    Sutter Medical Network
    Palo Alto, California

    Disclosures

    Disclosure: Frank dela Rama, RN, MSN, CNS, AGN-BC, AOCNS, has no relevant financial relationships.

Editors

  • Davecia Ragoonath-Cameron, MS

    Medical Education Director, Medscape, LLC 

    Disclosures

    Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships. 

  • Christin Melton, ELS

    Scientific Content Manager, Medscape, LLC 

    Disclosures

    Disclosure: Christin Melton, ELS, has disclosed no relevant financial relationships. 

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Personalizing Cancer Care in Nonmetastatic Castration-Resistant Prostate Cancer

Authors: Alicia K. Morgans, MD, MPH; Steven P. Ludlow, PharmD, BCOP, BCPS; Frank dela Rama, RN, MSN, CNS, AGN-BC, AOCNSFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 1/25/2022

Valid for credit through: 1/25/2023

processing....

Educational Impact Challenge

The goal of this activity is to improve the knowledge and confidence of oncologists, urologists, and other members of the healthcare team in creating more patient-centered treatment plans for nonmetastatic castration-resistant prostate cancer (nmCRPC) and actively engaging patients and caregivers in care-planning discussions to balance clinical outcomes with maintenance of quality of life.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print